FDA Lapse in Funding
In the absence of either an FY 2019 appropriation or a Continuing Resolution for FDA, beginning on December 22, 2018 and continuing until the date of enactment of an FY 2019 appropriation or Continuing Resolution ("lapse period"), agency operations continue to the extent permitted by law, such as activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fee funds. Read more
New Information for FDA Employees
** BREAKING NEWS: On Thursday, January 24, 2019, from 12:00-3:00 p.m., at the White Oak Campus, furloughed, excepted and partially exempt employees may participate in an employee outreach event to obtain information related to their current furlough status. **
Please be advised FDA is required to issue updated formal notices to all employees. For more information click HERE.
On January 16th, S.24 was signed into law. The Government Employee Fair Treatment Act of 2019, guarantees that federal workers who are furloughed or working without pay will be compensated for the period of the appropriations lapse beginning December 22, 2018. Employees will be paid retroactively once a FY19 appropriation or Continuing Resolution is approved. For more information click HERE
If you are an FDA employee with a question about the current lapse in appropriations funding, please email AskFDA2019@fda.hhs.gov. Depending on your furlough status please continue to monitor insideFDA or FDA.gov for available information on the current lapse in appropriations funding for the FDA. More information for employees
- Medications, homeopathic remedies and teething jewelry can be dangerous.
- Supporting and understanding the patient experience and incorporating patient feedback into our work is an agency-wide priority.
- How much do you know about that cup of coffee you drink each morning? There may be more to it than you think.
News & Events
- January 22, 2019 - Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on latest steps to strengthen FDA’s 510(k) program for premarket review of medical devices
- January 17, 2019 - Statement from FDA Commissioner Scott Gottlieb, M.D., on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths
- January 16, 2019 - FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy
Recent Consumer Updates
Browse by Audience
Updates and information for staying safe and healthy
Learn about other treatments, drug/device approvals, public meetings and more
For Health Professionals
Medical product safety information, adverse event/problem reporting and more
For Scientists & Researchers
NCTR, pediatrics, clinical trials, Critical Path Initiative, foods and veterinary medicine research, and more
Guidance, registration and listing, pay user fees, import programs and more
Perspectives from FDA Experts
January 9, 2019
The Future of FDA's Electronic Safety Surveillance